TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
9.96
-0.02 (-0.20%)
Feb 26, 2026, 4:00 PM EST - Market closed

TransCode Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
924832-
Market Cap Growth
35.84%-43.27%-51.10%-73.50%--
Enterprise Value
61-3-09-
Last Close Price
9.9894.366091.00497486.691877587.23-
PB Ratio
5.83-1.162.522.611.56-
P/TBV Ratio
6.42-2.522.611.56-
Debt / Equity Ratio
--0.020.28---0.61
Net Debt / Equity Ratio
-1.992.86-1.41-1.54-1.02-0.37
Net Debt / EBITDA Ratio
0.170.370.120.273.41-
Net Debt / FCF Ratio
0.200.430.130.313.77-2.55
Quick Ratio
1.022.100.791.158.222.05
Current Ratio
1.602.561.281.708.972.05
Return on Equity (ROE)
-1763.01%--759.85%-148.57%-80.53%-
Return on Assets (ROA)
-232.54%-157.06%-190.26%-76.30%-32.05%-72.09%
Return on Capital Employed (ROCE)
-754.60%-346.30%-1156.50%-575.00%-30.10%-111.70%
Earnings Yield
-296.50%-714.09%-448.43%-207.69%-21.44%-
FCF Yield
-158.68%-569.30%-437.89%-187.57%-17.30%-
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q